Tech Company Financing Transactions
NuProbe Funding Round
NuProbe, based in Houston, raised $50 million from AstraZeneca, CR-CP Life Science Fund and Panlin Capital.
Transaction Overview
Company Name
Announced On
6/3/2022
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
AstraZeneca (Lead Investor)
CR-CP Life Science Fund (Lead Investor)
Panlin Capital (Lead Investor)
Sequoia Capital (Neil Shen)
Proceeds Purpose
The funds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2575 West Bellfort Ave. 200
Houston, TX 77054
USA
Houston, TX 77054
USA
Phone
Website
Email Address
Overview
NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world's greatest challenges -- non-invasive early detection of rare genetic variants in patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yingshuang Chai
Co-Founder
Victor Shi
Co-Founder
Peng Yin
Co-Founder
David Zhang
VP - Bus. Development
Nicolas de Loubresse
VP - Manufacturing
Hu Ouyang
VP - Marketing
Song Gao
VP - R & D
Yundi Chen
VP - R & D
Junfeng Luo
VP - Sales
Yu Zhou
Browse more venture capital transactions:
Prev: 6/3/2022: Vernal Biosciences venture capital transaction
Next: 6/3/2022: Prokeep venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs